Pharmacotherapy of ‘treatment resistant’ type 2 diabetes

Expert Opinion on Pharmacotherapy

Volumn 18, Issue 5, 2017, Pages 503-515

  Scheen, André J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Combination therapy; DPP 4 inhibitor; GLP 1 receptor agonist; SGLT2 inhibitor; triple therapy; type 2 diabetes

Indexed keywords

ALBIGLUTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DULAGLUTIDE; EXENDIN 4; GLUCOSE TRANSPORTER 2; HEMOGLOBIN A1C; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE;

GLUCOTOXICITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LIFESTYLE; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TOTAL QUALITY MANAGEMENT; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; METABOLISM; OBESITY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; OBESITY; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS;

EID: 85016280743     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2017.1297424     Document Type: Review

References (154)

1. DeFronzo RA., Banting lecture. From the triumvirate to the ominous octet:a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015:a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetologia. 2015;58:429–442.•• Updated ADA-EASD position statement paper summarizing the strategies for a patient-centred approach for the management of hyperglycemia in type 2 diabetes.
3. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of clinical endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2016 executive summary. Endocr Pract. 2016;22:84–113.
4. Association AD. Standards of medical care in diabetes - 2017. Diabetes Care. 2017;40:S1–S135.•• Updated exhaustive document describing the standards of care in diabetes, including type 2 diabetes.
5. Tahrani AA, Barnett AH, Bailey CJ. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol. 2016;12:566–592.
6. Selvin E, Parrinello CM, Sacks DB, et al. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med. 2014;160:517–525.
7. Stone MA, Charpentier G, Doggen K, et al. Quality of care of people with type 2 diabetes in eight European countries:findings from the guideline adherence to enhance care (GUIDANCE) study. Diabetes Care. 2013;36:2628–2638.
8. de Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe:data from the PANORAMA study. Clin Endocrinol (Oxf). 2014;80:47–56.
9. So WY, Raboca J, Sobrepena L, et al. Comprehensive risk assessments of diabetic patients from seven Asian countries:the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes. 2011;3:109–118.
10. Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD:the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–3087.
11. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368:1613–1624.
12. Shojania KG, Ranji SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control:a meta-regression analysis. JAMA. 2006;296:427–440.
13. Tricco AC, Ivers NM, Grimshaw JM, et al. Effectiveness of quality improvement strategies on the management of diabetes:a systematic review and meta-analysis. Lancet. 2012;379:2252–2261.
14. Del Prato S, Felton AM, Munro N, et al. Improving glucose management:ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract. 2005;59:1345–1355.
15. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607.
16. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173–194.
17. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes:the scope of the problem. Diabetes Care. 2005;28:2543–2545.
18. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment:the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27(Suppl 3):13–20.
19. Oliveras A, de la Sierra A., Resistant hypertension:patient characteristics, risk factors, co-morbidities and outcomes. J Hum Hypertens. 2014;28:213–217.
20. White WB, Turner JR, Sica DA, et al. Detection, evaluation, and treatment of severe and resistant hypertension:proceedings from an American Society of hypertension interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. J Am Soc Hypertens. 2014;8:743–757.
21. Muxfeldt ES, de Souza F, Salles GF. Resistant hypertension:a practical clinical approach. J Hum Hypertens. 2013;27:657–662.
22. Crowley MJ, Holleman R, Klamerus ML, et al. Factors associated with persistent poorly controlled diabetes mellitus:clues to improving management in patients with resistant poor control. Chronic Illn. 2014;10:291–302.• This review paper describes the different strategies to target-specific barriers to improvement among patients whose diabetes is resistant to standard diabetes care.
23. Yin J, Yeung R, Luk A, et al. Gender, diabetes education, and psychosocial factors are associated with persistent poor glycemic control in patients with type 2 diabetes in the Joint Asia Diabetes Evaluation (JADE) program. J Diabetes. 2016;8:109–119.
24. Aronson R, Orzech N, Ye C, et al. Specialist-led diabetes registries and prevalence of poor glycemic control in type 2 diabetes:the Diabetes Registry Outcomes Project for A1C reduction (DROP A1C). Diabetes Care. 2016;39:1711–1717.
25. Khan H, Lasker SS, Chowdhury TA. Exploring reasons for very poor glycaemic control in patients with Type 2 diabetes. Prim Care Diabetes. 2011;5:251–255.
26. Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes:a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417.
27. Aronson R, Orzech N, Ye C, et al. Specialist-led diabetes registries and predictors of poor glycemic control in type 2 diabetes:insights into the functionally refractory patient from the LMC diabetes registry database. J Diabetes. 2016;8:76–85.
28. Carratala-Munuera MC, Gil-Guillen VF, Orozco-Beltran D, et al. Barriers associated with poor control in Spanish diabetic patients. A consensus study. Int J Clin Pract. 2013;67:888–894.
29. Yki-Jarvinen H. Glucose toxicity. Endocr Rev. 1992;13:415–431.
30. Cusi K. The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diabetes Rep. 2010;10:306–315.
31. Scheen AJ. Precision medicine:the future in diabetes care? Diabetes Res Clin Pract. 2016;117:12–21.
32. Keskin A, Unalacak M, Bilge U, et al. Effects of sleep disorders on hemoglobin A1c levels in type 2 diabetic patients. Chin Med J (Engl). 2015;128:3292–3297.
33. Pannala R, Basu A, Petersen GM, et al. New-onset diabetes:a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10:88–95.
34. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011;65:314–322.
35. Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007;30:807–812.
36. Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218–1224.
37. Pantalone KM, Wells BJ, Chagin KM, et al. Intensification of diabetes therapy and time until A1C goal attainment among patients with newly diagnosed type 2 diabetes who fail metformin monotherapy within a large integrated health system. Diabetes Care. 2016;39:1527–1534.
38. Asuzu CC, Walker RJ, Williams JS, et al. Pathways for the relationship between diabetes distress, depression, fatalism and glycemic control in adults with type 2 diabetes. J Diabetes Complications. 2017;31:169–174.
39. Walker RJ, Strom Williams J, Egede LE. Influence of race, ethnicity and social determinants of health on diabetes outcomes. Am J Med Sci. 2016;351:366–373.
40. Scheen AJ, Van Gaal LF. Combating the dual burden:therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:911–922.
41. Brown A, Desai M, Taneja D, et al. Managing highly insulin-resistant diabetes mellitus:weight loss approaches and medical management. Postgrad Med. 2010;122:163–171.
42. Look ARG, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–154.
43. Hainer V. Overview of new antiobesity drugs. Expert Opin Pharmacother. 2014;15:1975–1978.
44. Van Gaal L, Scheen A. Weight management in type 2 diabetes:current and emerging approaches to treatment. Diabetes Care. 2015;38:1161–1172.
45. Martinussen C, Bojsen-Moller KN, Svane MS, et al. Emerging drugs for the treatment of obesity. Expert Opin Emerg Drugs. 2016 Dec 16;1–13. [Epub ahead of print]
46. Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events:a systematic review and meta-analysis. JAMA. 2016;315:2424–2434.
47. Tomlinson B, Hu M, Zhang Y, et al. Investigational glucagon-like peptide-1 agonists for the treatment of obesity. Expert Opin Investig Drugs. 2016;25:1167–1179.
48. Rajeev SP, Cuthbertson DJ, Wilding JP. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition. Diabetes Obes Metab. 2016;18:125–134.
49. Scheen AJ, De Flines J, De Roover A, et al. Bariatric surgery in patients with type 2 diabetes:benefits, risks, indications and perspectives. Diabetes Metab. 2009;35:537–543.
50. Dixon JB, le Roux CW, Rubino F, et al. Bariatric surgery for type 2 diabetes. Lancet. 2012;379:2300–2311.
51. Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes:a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–877.
52. Levin PA. Practical combination therapy based on pathophysiology of type 2 diabetes. Diabetes Metab Syndr Obes. 2016;9:355–369.
53. Scheen AJ, Lefebvre PJ. Oral antidiabetic agents. A guide to selection. Drugs. 1998;55:225–236.
54. McIntosh B, Cameron C, Singh SR, et al. Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea:a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2012;6:e62–74.
55. Saulsberry WJ, Coleman CI, Mearns ES, et al. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int J Clin Pract. 2015;69:1221–1235.
56. Derosa G, Cicero AF, Franzetti IG, et al. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and beta-cell function:the triple oral therapy. Diabet Med. 2013;30:846–854.
57. Roberts VL, Stewart J, Issa M, et al. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione:results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2005;27:1535–1547.
58. Barnett AH, Charbonnel B, Moses RG, et al. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2015;31:1919–1931.
59. Scheen AJ. A review of gliptins for 2014. Exp Opin Pharmacother. 2015;16:43–62.
60. Lajara R. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Expert Opin Pharmacother. 2014;15:2565–2585.
61. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015;75:33–59.
62. Scheen AJ. SGLT2 inhibitors:benefit/risk balance. Curr Diabetes Rep. 2016;16:92.
63. Zonszein J, Groop PH. Strategies for diabetes management:using newer oral combination therapies early in the disease. Diabetes Ther. 2016;7:621–639.
64. Mearns ES, Saulsberry WJ, White CM, et al. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes:a network meta-analysis. Diabet Med. 2015;32:1530–1540.• This network meta-analysis compares the efficacy and safety of different glucose-lowering medications when added to metformin and a sulphonylurea.
65. Gross JL, Kramer CK, Leitao CB, et al. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes:a network meta-analysis. Ann Intern Med. 2011;154:672–679.
66. Downes MJ, Bettington EK, Gunton JE, et al. Triple therapy in type 2 diabetes; a systematic review and network meta-analysis. Peer J. 2015;3:e1461.
67. Lozano-Ortega G, Goring S, Bennett HA, et al. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea. Curr Med Res Opin. 2016;32:807–816.
68. Derosa G, Salvadeo SA, D’Angelo A, et al. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin:a double-blind, cross-over, clinical trial. Curr Med Res Opin. 2009;25:607–615.
69. Scheen AJ, Tan MH, Betteridge DJ, et al. Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17). Diabet Med. 2009;26:1033–1039.
70. Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733–745.
71. Moses RG, Round E, Shentu Y, et al. A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control. J Diabetes. 2016;8:701–711.
72. Lukashevich V, Prato SD, Araga M, et al. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab. 2014;16:403–409.
73. Moses RG, Kalra S, Brook D, et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab. 2014;16:443–450.
74. Owens DR, Swallow R, Dugi KA, et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea:a 24-week randomized study(1). Diabet Med. 2011;28:1352–1361.
75. Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea:a randomised trial. Int J Clin Pract. 2013;67:1267–1282.
76. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea:a 52-week randomized trial. Diabetes Care. 2013;36:2508–2515.
77. Matthaei S, Bowering K, Rohwedder K, et al. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea:a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38:365–372.
78. Haering HU, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110:82–90.
79. Bosi E, Ellis GC, Wilson CA, et al. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone:a 52-week, randomized, double-blind, active-controlled, parallel-group study. Diabetes Obes Metab. 2011;13:1088–1096.
80. DeFronzo RA, Burant CF, Fleck P, et al. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:1615–1622.
81. Bajaj M, Gilman R, Patel S, et al. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone:a 24-week randomized, double-blind study. Diabet Med. 2014;31:1505–1514.
82. Fonseca V, Staels B, Morgan JD, 2nd, et al. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes. J Diabetes Complications. 2013;27:177–183.
83. Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014;16:467–477.
84. Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes:a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014;16:147–158.
85. Harris SB. The power of two:an update on fixed-dose combinations for type 2 diabetes. Expert Rev Clin Pharmacol. 2016 Sep 12; 1–10. [Epub ahead of print]
86. Bell DS. Combine and conquer:advantages and disadvantages of fixed-dose combination therapy. Diabetes Obes Metab. 2013;15:291–300.
87. Abdulsalim S, Peringadi Vayalil M, Miraj SS. New fixed dose chemical combinations:the way forward for better diabetes type II management? Expert Opin Pharmacother. 2016;17:2207–2214.• This review paper describes the safety and efficacy data of newer FDCs available as an adjuvant therapy to conventional pharmacological interventions in type 2 diabetes.
88. Blonde L, San Juan ZT. Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther. 2012;29:1–13.
89. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes:a systematic review and meta-analysis. Ann Intern Med. 2016;164:740–751.
90. Scheen AJ. Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes. Expert Opin Drug Metab Toxicol. 2015;11:1005–1020.
91. Barner JC. Adherence to oral antidiabetic agents with pioglitazone and metformin:comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy. Clin Ther. 2011;33:1281–1288.
92. Scheen AJ. DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes:from rationale to clinical aspects. Expert Opin Drug Metab Toxicol. 2016;12:1407–1417.• This narrative review explains the rationale and describes both the efficacy and safety of a DPP-4 inhibitor plus SGLT-2 inhibitor combination in the management of type 2 diabetes.
93. Scheen AJ. Pharmacokinetic characteristics and clinical efficacy of an SGLT2 inhibitor plus DPP-4 inhibitor combination therapy in type 2 diabetes. Clin Pharmacokinet. 2016 Dec 30. doi:10.1007/s40262-016-0498-9. [Epub ahead of print]
94. Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH. EMPA-REG and other cardiovascular outcome trials of glucose-lowering agents:implications for future treatment strategies in type 2 diabetes mellitus. Clin Ther. 2016;38:1288–1298.
95. Rosenstock J, Hansen L, Zee P, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy:a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38:376–383.
96. DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015;38:384–393.
97. Pratley R, Eldor R, Golm G, et al. Safety and efficacy of ertugliflozin plus sitagliptin versus either treatment alone in subjects with type 2 diabetes mellitus inadequately controlled with metformin:the VERTIS FACTORIAL trial. Communication presented at the 52nd meeting of the European Association for the Study of Diabetes; 2016 Sep 12-16; Munich, Germany. (abstract 728).
98. Jabbour SA, Hardy E, Sugg J, et al. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin:a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014;37:740–750.
99. Mathieu C, Ranetti AE, Li D, et al. Randomized, double-blind, phase 3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015;38:2009–2017.
100. Mathieu C, Herrera Mamolejo M, Gonzalez Gonzalez JG, et al. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:1134–1137.
101. Softeland E, Meier JJ, Vangen B, et al. Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin:a 24-week randomized, double-blind, parallel-group trial. Diabetes Care. 2017;40:201–209.
102. Rodbard HW, Seufert J, Aggarwal N, et al. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin. Diabetes Obes Metab. 2016;18:812–819.
103. Lauring B, Eldor R, Liu J, et al. Efficacy and safety of ertugliflozin in subjects with type 2 diabetes mellitus inadequately controlled on the dual combination of metformin and sitagliptin:the VERTIS SITA2 trial. Oral Presentation at the 52nd Annual Meeting of the European Association for the Study of Diabetes; 2016 Sep 12-16; Munich, Germany.
104. Matthaei S, Catrinoiu D, Celinski A, et al. Randomized, double-blind trial of triple therapy with saxagliptin add-on to dapagliflozin plus metformin in patients with type 2 diabetes. Diabetes Care. 2015;38:2018–2024.
105. Matthaei S, Aggarwal N, Garcia-Hernandez P, et al. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes Obe Metab. 2016;18:1128–1133.
106. Tong WT, Vethakkan SR, Ng CJ. Why do some people with type 2 diabetes who are using insulin have poor glycaemic control? A qualitative study. BMJ Open. 2015;5:e006407.
107. Church TJ, Haines ST. Treatment approach to patients with severe insulin resistance. Clin Diabetes. 2016;34:97–104.
108. Vos RC, van Avendonk MJ, Jansen H, et al. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. Cochrane Database Syst Rev. 2016;9:CD006992.• This Cochrane review compares the positive effects on glycemic control of the addition of all oral glucose-lowering agents (except SGLT2 inhibitors) in patients with type 2 diabetes and inadequate glycemic control despite insulin therapy.
109. Pugh JA, Wagner ML, Sawyer J, et al. Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis. Diabetes Care. 1992;15:953–959.
110. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996;156:259–264.
111. Hemmingsen B, Christensen LL, Wetterslev J, et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes:systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ. 2012;344:e1771.
112. Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in type 2 diabetes:systematic review and meta-analysis. PLoS One. 2009;4:e6112.
113. Kim YG, Min SH, Hahn S, et al. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes:a systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;116:86–95.
114. Tang H, Cui W, Li D, et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus:a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:142–147.• This recent meta-analysis of controlled randomised trials evaluates the efficacy and safety of adding a SGLT2 inhibitor to insulin therapy for treating inadequately controlled type 2 diabetes.
115. Scheen AJ. Combined thiazolidinedione-insulin therapy - should we be concerned about safety? Drug Saf. 2004;27:841–856.
116. Charbonnel B, DeFronzo R, Davidson J, et al. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19). J Clin Endocrinol Metab. 2010;95:2163–2171.
117. Nauck M. Incretin therapies:highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18:203–216.
118. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742.
119. Cimmaruta D, Maiorino MI, Scavone C, et al. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus:a systematic review. Expert Opin Drug Saf. 2016;15:77–83.
120. Wang Y, Li L, Yang M, et al. Glucagon-like peptide-1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus:a meta-analysis of clinical trials. Diabetes Obes Metab. 2011;13:972–981.
121. Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes:a systematic review and meta-analysis. Lancet. 2014;384:2228–2234.• This meta-analysis demonstrates that GLP-1 agonist and basal insulin combination treatment can enable achievement of robust glycemic control with no increased hypoglycemia or weight gain.
122. Abd El Aziz MS, Kahle M, Meier JJ, et al. A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients. Diabetes Obes Metab. 2017;19:216–227.
123. Zhong X, Zhang T, Liu Y, et al. Effects of three injectable antidiabetic agents on glycaemic control, weight change and drop-out in type 2 diabetes suboptimally controlled with metformin and/or a sulfonylurea:a network meta-analysis. Diabetes Res Clin Pract. 2015;109:451–460.
124. Liu FP, Dong JJ, Yang Q, et al. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes:a systematic review and meta-analysis. J Diabetes. 2015;7:322–328.
125. Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes:a randomized trial. Ann Intern Med. 2005;143:559–569.
126. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47.
127. Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3):an open-label randomised trial. Lancet. 2010;375:2234–2243.
128. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU):a randomised controlled trial. Diabetologia. 2009;52:2046–2055.
129. Rosenstock J, Hanefeld M, Shamanna P, et al. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). J Diabetes Complications. 2014;28:386–392.
130. Giorgino F, Benroubi M, Sun JH, et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38:2241–2249.
131. Home PD, Shamanna P, Stewart M, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride:HARMONY 5. Diabetes Obes Metab. 2015;17:179–187.
132. Weissman PN, Carr MC, Ye J, et al. HARMONY 4:randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014;57:2475–2484.
133. Singh S, Wright EE, Jr., Kwan AY, et al. Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus:a systematic review and meta-analysis. Diabetes Obes Metab. 2017;19:228–238.
134. Wysham C, Blevins T, Arakaki R, et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care. 2014;37:2159–2167.
135. Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther. 2012;34:2082–2090.
136. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32:1224–1230.
137. Reusch J, Stewart MW, Perkins CM, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial):52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014;16:1257–1264.
138. Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for type 2 diabetes (EDICT):a randomized trial. Diabetes Obes Metab. 2015;17:268–275.
139. Freemantle N, Mamdani M, Vilsboll T, et al. IDegLira versus alternative intensification strategies in patients with type 2 diabetes inadequately controlled on basal insulin therapy. Diabetes Ther. 2015;6:573–591.
140. Rosenstock J, Guerci B, Hanefeld M, et al. Prandial options to advance basal insulin glargine therapy:testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes:the GetGoal Duo-2 trial. Diabetes Care. 2016;39:1318–1328.
141. Forst T. Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2016;17:1703–1708.
142. Stinkens K, Peene B, Mathieu C. Insulin degludec + liraglutide:a complementary combination. Expert Opin Biol Ther. 2016;16:1171–1177.
143. Nauck MA, Kahle M, Baranov O, et al. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide:a randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19:200–207.
144. Fulcher G, Matthews DR, Perkovic V, et al. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2016;18:82–91.
145. Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8):a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004–1016.• This paper reports the results of the first clinical trial demonstrating the efficacy and safety of the combination of a GLP-1 receptor agonist and a SGLT2 inhibitor for the management of type 2 diabetes.
146. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
147. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
148. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
149. Rajpathak SN, Rajgopalan S, Engel SS. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy. J Diabetes Complications. 2014;28:831–835.
150. Phung OJ, Sobieraj DM, Engel SS, et al. Early combination therapy for the treatment of type 2 diabetes mellitus:systematic review and meta-analysis. Diabetes Obes Metabol. 2014;16:410–417.
151. Bailey T. Options for combination therapy in type 2 diabetes:comparison of the ADA/EASD position statement and AACE/ACE algorithm. Am J Med. 2013;126:S10–20.
152. Cahn A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care. 2016;39(Suppl 2):S137–45.
153. Qiu Y, Li Q, Tang J, et al. Why physicians do not initiate dual therapy as recommended by AACE guidelines:a survey of clinicians in the United States. Diabetes Res Clin Pract. 2015;108:456–465.
154. Bailey CJ, Tahrani AA, Barnett AH. Future glucose-lowering drugs for type 2 diabetes. Lancet Diabetes Endocrinol. 2016;4:350–359.